Viewing Study NCT02771808



Ignite Creation Date: 2024-05-06 @ 8:36 AM
Last Modification Date: 2024-10-26 @ 12:02 PM
Study NCT ID: NCT02771808
Status: COMPLETED
Last Update Posted: 2016-05-13
First Post: 2010-09-17

Brief Title: Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients
Sponsor: University of Virginia
Organization: University of Virginia

Study Overview

Official Title: Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients
Status: COMPLETED
Status Verified Date: 2016-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Specific aim 1a will test the hypothesis that diabetic patients with 2-2 haptoglobin genotype have higher indices of postoperative myocardial injury creatine kinase MB isoenzyme Troponin I and renal injury as indicated by elevated creatinine cytostatin C and glomerular filtration rate Of note significantly elevated levels 5 times the upper normal limit of creatine kinase MB isoenzyme and troponins postoperatively have been associated with postoperative myocardial ischemiainfarction and are a predictor of short-term and long-term mortality after cardiac surgery

Specific aim 1b will evaluate preoperative and postoperative indices of oxidative stress such as isoprostane f2 alpha and malondialdehyde and will evaluate whether patients with type 2-2 haptoglobin express increased oxidative stress The investigators will also try to correlate whether patients with increased oxidative stress are those with elevated indices of myocardial andor renal injury Specific aim 1c will try to evaluate whether patients with type 2-2 haptoglobin also have increased levels of inflammatory indices C-reactive proteininterleukin IL-1 IL-2 IL-6 TNFtumor necrosis factor and try to correlate the findings with postoperative myocardial and or renal injury

The incidence of atrial fibrillation after coronary artery bypass graft ranges from 19 to 27 The investigators will also look at any correlation of the type 2-2 haptoglobin and the incidence of post-operative atrial fibrillation
Detailed Description: Diabetes mellitus is a major risk factor for postoperative morbidity and mortality after cardiac surgery mainly because of accelerated atherosclerosis and target-organ injury that predispose these patients to increased incidence of postoperative morbidity such as but not limited to postoperative adverse cardiac events renal injury or stroke and mortality

Over the past several years haptoglobin has been identified as a risk factor that predicts the development of cardiovascular complications in diabetics There are 3 major haplotypes of haptoglobin 1-1 1-2 and 2-2 Several studies have demonstrated that diabetic individuals with the 2-2 genotype have up to 5 fold increased risk to develop cardiovascular complications as compared to diabetic patients with a non-2-2 haptoglobin genotype There is no data in the literature that evaluated whether the haptoglobin 2-2 genotype is a risk factor for increased postoperative morbidity andor mortality after cardiac surgery in patients with DM

Therefore the aims of the study are to evaluate whether diabetic patients with the 2-2 genotype are at increased risk for postoperative morbidity andor mortality after cardiac surgery

Preliminary studies in diabetic patients demonstrated that those with haptoglobin 2-2 genotype are at increased risk for cardiovascular complications of diabetes Moreover these patients were found to have increased in-hospital mortality after acute MI compared to diabetic individuals that do not have the 2-2 genotype and they also suffer from increased incidence of post catheterization stent thrombosis compared to diabetics that do not have the 2-2 genotype

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None